<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336383">
  <stage>Registered</stage>
  <submitdate>15/02/2011</submitdate>
  <approvaldate>15/02/2011</approvaldate>
  <actrnumber>ACTRN12611000181909</actrnumber>
  <trial_identification>
    <studytitle>Efficacy and safety of artesunate tablet and drug combination (dihydroartemisinin  piperaquine)  for the treatment of uncomplicated Plasmodium falciparum malaria and chloroquine for vivax malaria in 5 sentinel sites  (Binh Phuoc, Dak Nong, Gia Lai, Ninh Thuan and  Quang Tri provinces), Viet Nam in 2008 and 2009</studytitle>
    <scientifictitle>Efficacy and safety of artesunate tablet and drug combination (dihydroartemisinin  piperaquine)  for the treatment of uncomplicated Plasmodium falciparum malaria and chloroquine for vivax malaria in 5 sentinel sites  (Binh Phuoc, Dak Nong, Gia Lai, Ninh Thuan and  Quang Tri provinces), Viet Nam in 2008 and 2009</scientifictitle>
    <utrn>U1111-1118-9072</utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Malaria</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Studies of infection and infectious agents</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>The efficacy and safety of 3 drugs used by the control program as anti-malarial standard treatment, artesunate, DHA-PIP and CQ, will be assessed separately in 9 different groups of patients in 5 different study sites. Pf malaria patients in Binh Phuoc and Ninh Thuan sites will receive Artesunate for 7 days in 2008 and in Quang Tri site in 2009.  Pf malaria patients in Quang Tri, Gia Lai sites will receive DHA-PIP for 3 days in 2008 and in Binh Phuoc, Dak Nong sites in 2009. Pv malaria patients in Ninh Thuan and Binh phuoc will receive  CQ for 3 days in 2009.
- Oral artesunate (50 mg/tab) will be administered at a total dose of 16 mg/kgbw over 7 days (1st day: 4 mg/kgbw, 2nd to 7th days: 2 mg/kgbw/day). 
- Oral dihydroartemisinin-piperaquine(DHA-PIP) will be administered at a dose of 2mg/kg/day DHA and 16mg/kg/day PIP for 3 days.
- Oral chloroquine will be administered at a total dose of 25mg/kgbw (10 mg/kgbw on day0, 10mg/kgbw on day1 and 5 mg/kgbw on day2).
The WHO 28 day in vivo protocol, used in this study, consists of parasite count and temperature measurements at baseline (day0 before dosing) and on days 1, 2, 3, 7, 14, 21 and 28.</interventions>
    <comparator>single group trials</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>28-day cure rate or ACPR (adequate clinical and parasitological response) (absence of Parasitemia on day 28, irrespective of axillary temparature, in patients who did not previously meet any of the criteria of early treatment failure, late clinical failure of late parasitological failure).</outcome>
      <timepoint>after start of the study: Day 1, Day 2, Day 3, Day 7, Day 14, Day 21 and D28.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>PCR-corrected ACPR  (PCR: polymerase chain reaction, a molecular tool/test to differentiate if the failure is a true resistance or reinfection)</outcome>
      <timepoint>after start of the study (Day 7, Day 14, Day 21 and Day 28)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>- Adults and children over 6 months old;
- single Infection with P. falciparum;
- Parasitaemia:  1 000200 000 asexual forms per micro ml of blood;
- Presence of  axillary temperature greater than or eqqual 37.5 degrees Centigrade or  history of fever within the previous 24 h;
- Ability to swallow oral medication;
- Ability and willingness to comply with the study protocol for the duration of the study and to comply with the study visit schedule;
- Informed consent from the patient or from a parent or guardian in case of children.</inclusivecriteria>
    <inclusiveminage>6</inclusiveminage>
    <inclusiveminagetype>Months</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>- Presence of general danger signs among children &lt;5 years old or other signs of severe and complicated falciparum malaria according to current WHO definitions.
- Mixed or mono-infection with another Plasmodium species;
- Presence of severe malnutrition 
- Presence of febrile conditions due to diseases other than malaria (measles, acute lower tract respiratory infection, severe diarrhoea with dehydration, etc.), or other known underlying chronic or severe diseases (e.g. cardiac, renal, hepatic diseases, HIV/AIDS);
- History of hypersensitivity reactions to any of the drug(s) being tested or used as alternative treatment;
- Positive pregnancy test or lactating</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/09/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>500</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up complete</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Viet Nam</country>
      <state>Gia Lai</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Viet Nam</country>
      <state>Quang Tri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Viet Nam</country>
      <state>Ninh Thuan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Viet Nam</country>
      <state>Binh phuoc</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Ministry of Health</primarysponsorname>
    <primarysponsoraddress>138A Giang vo street, Ba Dinh, Ha Noi, 10.000</primarysponsoraddress>
    <primarysponsorcountry>Viet Nam</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Other</fundingtype>
      <fundingname>WHO</fundingname>
      <fundingaddress>World Health Organization Western Pacific Regional Office, United Nations Avenue, Manila 1000</fundingaddress>
      <fundingcountry>Philippines</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Other</fundingtype>
      <fundingname>Global funds</fundingname>
      <fundingaddress>Ministry of Health
138A, Giang vo street, Ba Dinh, Ha Noi, 10.000</fundingaddress>
      <fundingcountry>Viet Nam</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Other</sponsortype>
      <sponsorname>IMPE Ho Chi Minh</sponsorname>
      <sponsoraddress>699 Tran Hung Dao, Ward 5, Ho Chi Minh city, 70.000</sponsoraddress>
      <sponsorcountry>Viet Nam</sponsorcountry>
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Other</sponsortype>
      <sponsorname>IMPE Qui Nhon</sponsorname>
      <sponsoraddress>611B, Nguyen Thai Hoc Street, Quinhon city, Binh Dinh Province, 53.000</sponsoraddress>
      <sponsorcountry>Viet Nam</sponsorcountry>
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Other Collaborative groups</othercollaboratortype>
      <othercollaboratorname>Binh Phuoc Malaria center</othercollaboratorname>
      <othercollaboratoraddress>14 road, Tien Thanh commune, Dong Xoai town, Binh Phuoc province, 77.000</othercollaboratoraddress>
      <othercollaboratorcountry>Viet Nam</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other Collaborative groups</othercollaboratortype>
      <othercollaboratorname>Ninh Thuan  Malaria center</othercollaboratorname>
      <othercollaboratoraddress>156 Ngo Gia Tu street, Phan Rang - Thap Cham city, Ninh Thuan Province, 63.000</othercollaboratoraddress>
      <othercollaboratorcountry>Viet Nam</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other Collaborative groups</othercollaboratortype>
      <othercollaboratorname>Dak Nong malaria center</othercollaboratorname>
      <othercollaboratoraddress>Nghia Tan  commnue, Gia Nghia town, Dak Nong Province, 64.000</othercollaboratoraddress>
      <othercollaboratorcountry>Viet Nam</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other Collaborative groups</othercollaboratortype>
      <othercollaboratorname>Gia Lai Malaria center</othercollaboratorname>
      <othercollaboratoraddress>63 Phan Dinh Phung street, Pleiku city, Gia lai province, 54.000</othercollaboratoraddress>
      <othercollaboratorcountry>Viet Nam</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other Collaborative groups</othercollaboratortype>
      <othercollaboratorname>Quang Tri Malaria center</othercollaboratorname>
      <othercollaboratoraddress>Hoang Dieu street, Dong Ha city, Quang tri Province, , 46.000</othercollaboratoraddress>
      <othercollaboratorcountry>Viet Nam</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This surveillance study is a one-arm prospective evaluation of the clinical and parasitological responses to directly observed treatment for uncomplicated malaria. The objective is to assess the efficacy and safety of dihydroartemisinin-piperaquine (DHA-PIP) and artesunate (AS7) monotherapy for the treatment of uncomplicated Plasmodium falciparum malaria and chloroquine (CQ) for the treatment of Plasmodium vivax malaria in 5 sites in Vietnam.  The drugs and study sites are: AS7 in Bu Dang of Binh Phuoc, Huong Hoa of Quang Tri and Bac Ai of Ninh Thuan, DHA-PIP in Gia Lai, Quang Tri, Binh phuoc, and Dak Nong,  CQ in Ninh Son of  Ninh Thuan and Bu Dang of Binh Phuoc,  Viet Nam.  The WHO 28-day in vivo protocol will be used.  People with uncomplicated malaria who meet the study inclusion criteria will be enrolled, treated on site with the ACT DHA-PIP or 7-day artesunate monotherapy for Pf cases and CQ for Pv cases, and monitored weekly for 28 days. The follow-up consists of a fixed schedule of check-up visits and corresponding clinical and laboratory examinations. On the basis of the results of these assessments, the patients will be classified as having therapeutic failure (early or late) or an adequate response. The proportion of patients experiencing therapeutic failure during the follow-up period will be used to estimate the efficacy of the study drug. PCR analysis will be used to distinguish between a true recrudescence or reinfection.  The results of this study will be used to assist the Ministry of Health of Viet Nam in assessing the current national treatment guidelines for uncomplicated P. falciparum and P. vivax malaria.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Ethics Committee of National Institute of Malarialogy, Parasitology and Entomology</ethicname>
      <ethicaddress>245 Luong The Vinh street, Trung Van, Tu Liem, Hanoi, 10.200</ethicaddress>
      <ethicapprovaldate>10/08/2008</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>30/07/2008</ethicsubmitdate>
      <ethiccountry>Viet Nam</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>WHO WPRO Ethics Review Committee (ERC)</ethicname>
      <ethicaddress>WHO Western Pacific Regional Office, United NAtionas Avenue, Manila 1000.</ethicaddress>
      <ethicapprovaldate>2/10/2008</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>6/09/2008</ethicsubmitdate>
      <ethiccountry>Philippines</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Ta Thi Tinh</name>
      <address>Head of malaria Research and Treatment
 245 Luong The Vinh street, Trung Van, Tuliem, Hanoi
10.200</address>
      <phone>+84 912 684 889</phone>
      <fax>+ 84 38543015</fax>
      <email>tinhnimpe@yahoo.com</email>
      <country>Viet Nam</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Tran Cong Dai</name>
      <address>WHO - Vietnam
63 Tran Hung Dao, Hanoi, 10.000</address>
      <phone>+84 913201706</phone>
      <fax />
      <email>TranCongD@wpro.who.int</email>
      <country>Viet Nam</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Ta Thi Tinh</name>
      <address>Head of malaria Research and Treatment
245 Luong The Vinh street, Trung Van, Tuliem, Hanoi
10.200</address>
      <phone>+84 912 684 889</phone>
      <fax>+84 4 38543015</fax>
      <email>tinhnimpe@yahoo.com</email>
      <country>Viet Nam</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>